Lv5
940 积分 2021-09-15 加入
Phase I study of nivolumab or nivolumab/cisplatin/gemcitabine to treat unresectable/recurrent biliary tract cancer
3年前
已完结
Abstract 2680: Exploration of tumor environment classification using mIHC in pan-cancer tissue samples
3年前
已关闭
Characterization of hyperprogressive disease in patients with advanced biliary tract cancer treated with anti-PD-1 inhibitor: A multicenter retrospective study
3年前
已关闭
New approaches in developmental therapies for patients with biliary tract cancer
3年前
已完结
Genomic alterations predict clinical response to systemic chemotherapy and immune checkpoint blockade in biliary tract cancer
3年前
已完结
The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer
3年前
已完结
The prognostic role of soluble transforming growth factor-β related with soluble programmed death-ligand 1 in biliary tract cancer
3年前
已关闭
Efficacy and safety of pembrolizumab in patients with PD-L1 positive advanced biliary tract cancer (BTC): A prospective cohort study
3年前
已关闭
A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer
3年前
已关闭
GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer
3年前
已完结
皖公网安备34019202002308
